[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial
Louise Emmett(Garvan Institute of Medical Research), Shalini Subramaniam(University of Sydney), Megan Crumbaker(The Kinghorn Cancer Centre), Andrew Nguyen(St Vincent's Hospital Sydney), Anthony M. Joshua(Garvan Institute of Medical Research), Andrew Weickhardt(Austin Health), Sze-Ting Lee(Olivia Newton-John Cancer Wellness & Research Centre), Siobhan Ng(Sir Charles Gairdner Hospital), Roslyn J. Francis(University of Western Australia), Jeffrey C. Goh(Royal Brisbane and Women's Hospital), David A. Pattison(Royal Brisbane and Women's Hospital), Thean Hsiang Tan(Royal Adelaide Hospital), Ian Kirkwood(Royal Adelaide Hospital), Craig Gedye(Calvary Mater Newcastle Hospital), Natalie Rutherford(Hunter New England Local Health District), Shahneen Sandhu(University of Melbourne), Aravind Ravi Kumar(Peter MacCallum Cancer Centre), David Pook(Monash Health), Shakher Ramdave(Monash Health), David Nadebaum(Alfred Health), Mark Voskoboynik(Alfred Health), Andrew Redfern(Fiona Stanley Hospital), W A Macdonald(Fiona Stanley Hospital), Laurence E. Krieger(Royal North Shore Hospital), Geoffrey Schembri(Royal North Shore Hospital), Wei Chua(Western Sydney University), Peter Lin(South Western Sydney Local Health District), Lisa G. Horvath(Chris O’Brien Lifehouse), Patricia Bastick(St George Hospital), Patrick Butler(St George Hospital), Alison Yan Zhang(Macquarie University), Sonia Yip(National Health and Medical Research Council), Hayley Thomas(University of Sydney), Ailsa Langford(University of Sydney), Michael S. Hofman(University of Melbourne), Margaret McJannett(Australian and New Zealand Urogenital and Prostate Cancer Trials Group), Andrew Martin(National Health and Medical Research Council), Martin R. Stockler(Chris O’Brien Lifehouse), Ian D. Davis(Eastern Health)
Cited by 146
Abstract
Related Papers
No related papers found
Powered by citation graph analysis